Bladder cancer is not a single disease. Tumours that appear similar under a microscope can behave very differently, relapse at different rates and respond to entirely different treatments. Urothelial carcinoma, the most common form, is shaped by a complex mixture of genetic alterations, immune activity and changes in the tumour environment. Traditional clinical factors—such as tumour stage, grade, recurrence history and lymph-node involvement—remain essential, but they cannot fully explain this biological diversity. Biomarker testing offers a way to add that missing layer of information.

The group’s central message is that testing must be connected to a clinical decision. A biomarker is “actionable” when its result can influence treatment, surveillance or eligibility for a clinical trial. In bladder cancer, this may include alterations in the fibroblast growth factor receptor pathway, especially FGFR3, which can make some advanced tumours susceptible to FGFR-directed therapy. Other potentially relevant markers include programmed death-ligand 1, or PD-L1, which can help inform the use of immune checkpoint inhibitors in selected settings, as well as DNA repair defects, microsatellite instability and mismatch-repair deficiency, all of which may indicate an unusual sensitivity to immunotherapy.

The recommendations also highlight the importance of assessing HER2 biology, an area that has become increasingly relevant as antibody–drug conjugates and other targeted approaches expand. HER2 testing is not simply a matter of recording whether the protein is present or absent. Different laboratory methods can measure protein expression or gene amplification, and the result may depend on the assay, scoring system and quality of the tissue sample. Such technical details can determine whether a patient is correctly identified for a treatment opportunity, making standardized pathology procedures a critical part of precision oncology.

Timing is another major issue. Molecular information may be useful at diagnosis, before surgery, after recurrence or when metastatic disease develops, but the most informative sample can change as the cancer evolves. A tumour treated with chemotherapy, radiation, immunotherapy or targeted drugs may acquire new genetic features that were not present in the original biopsy. For this reason, the group supports a dynamic approach in which previously collected tissue is used when appropriate, while fresh tumour material—or, in selected circumstances, circulating tumour DNA from a blood sample—is considered when the disease changes.

This evolving biology creates a practical challenge for clinicians. A negative result from an old biopsy does not necessarily mean that a target is absent from a later tumour, just as a positive result may not guarantee that a treatment will work. Biomarkers are probabilities, not biological promises. Their interpretation must be combined with disease stage, previous therapies, organ function, patient preferences and the strength of evidence supporting a particular drug. The recommendations therefore emphasize multidisciplinary decision-making involving urologists, medical oncologists, pathologists, radiologists and molecular specialists.

The article also addresses the risk of fragmented testing. In many health systems, biomarker analysis is performed only after a patient has progressed through several lines of therapy, by which time an important treatment window may have passed. Tests may also be ordered inconsistently, interpreted using different criteria or delayed by limited access to specialized laboratories. The International Bladder Cancer Group calls for clearer testing pathways, validated assays and reporting systems that explain not only the molecular finding but also its clinical meaning, the available treatment options and the level of evidence behind them.

For patients, the shift could transform conversations about treatment. Instead of receiving a broadly defined diagnosis followed by a standard sequence of therapies, some individuals may be offered a strategy tailored to the molecular vulnerabilities of their cancer. A person whose tumour contains an actionable FGFR3 alteration, for example, may be considered for a pathway-specific drug, while another patient with immune-related biomarkers could be evaluated for checkpoint blockade. Those without an established target may be directed toward trials testing new combinations, novel antibody–drug conjugates or strategies designed to overcome resistance.

Yet precision medicine will not succeed through testing alone. The group stresses that biomarkers must be clinically validated, accessible and used equitably. Many promising molecular signals have not produced reliable benefits in large trials, and some tests remain too expensive or technically demanding for routine use. There is also a danger that unequal access to genomic profiling will widen existing differences in cancer outcomes. Integrating biomarkers into care therefore requires investment in laboratory quality, data interpretation, clinician education and reimbursement, alongside transparent communication with patients.

The wider significance of the recommendations reaches beyond bladder cancer. They represent a blueprint for moving from a one-size-fits-most model toward treatment decisions that reflect the biological identity of each tumour. As more targeted therapies and immunotherapies enter the clinic, the value of a biomarker will depend increasingly on how rapidly and accurately it can connect a patient to the right option. The International Bladder Cancer Group’s message is clear: molecular testing should not be an afterthought in bladder cancer care. It should become part of the clinical infrastructure that links diagnosis, treatment selection and the next generation of research.

Subject of Research: Bladder cancer biomarkers and their integration into clinical diagnosis, treatment selection, surveillance and precision oncology.

Article Title: Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

Article References: Hensley, P.J., Teoh, J.Y.C., Li, R. et al. Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group. Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01179-y

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01179-y

Keywords: bladder cancer, urothelial carcinoma, biomarkers, precision oncology, FGFR3, HER2, PD-L1, immunotherapy, targeted therapy, molecular testing, circulating tumour DNA, cancer care.

A groundbreaking study published in BMC Cancer (2025) takes a deep dive into this pressing gap in bladder cancer research, unveiling a comprehensive prognostic signature by combining hypoxia and lactate metabolism-related genes. Employing a multifaceted bioinformatics approach coupled with rigorous experimental validation, researchers established a novel risk scoring system with remarkable ability to predict patient outcomes and shed light on bladder cancer heterogeneity. This work not only paves the way for more precise prognostication but also holds promise in guiding personalized therapeutic strategies for a notoriously difficult-to-treat cancer.

The investigators leveraged large-scale genomic data from The Cancer Genome Atlas (TCGA), applying unsupervised machine learning via the k-means clustering algorithm to stratify bladder cancer patients into distinct molecular subtypes. This initial classification revealed two predominant subgroups, each exhibiting unique molecular signatures reflective of differing hypoxia and lactate metabolism patterns. By focusing on genes associated specifically with hypoxia and lactate pathways, the team embarked on a rigorous gene selection process, featuring univariate Cox regression, random forest modeling, and stepwise multivariate Cox regression analyses to distill a robust prognostic model.

This analytical pipeline culminated in a 9-gene signature, a biomarker panel that performed with exceptional efficacy in predicting overall survival among bladder cancer patients. Those scoring high on this risk model uniformly displayed poorer prognoses, underscoring the clinical utility of this signature for risk stratification. Beyond prognostication, the model unveiled striking correlations between high-risk patients and an abundance of tumor-promoting immune cells—detected through sophisticated immune infiltration analyses—alongside an overall dampened immune functionality within the tumor microenvironment.

Such immune profiles have profound therapeutic implications. Intriguingly, patients with elevated risk scores also appeared less responsive to conventional immunotherapies and standard chemotherapeutic regimens, hinting at underlying resistance mechanisms driven by hypoxia and altered lactate metabolism. Furthermore, the study found that these high-risk tumors predominantly aligned with the basal molecular subtype of bladder cancer, a category characterized by aggressive clinical features and poor treatment outcomes. This finding reinforces the notion that metabolic and microenvironmental features are deeply intertwined with molecular taxonomy in bladder cancer.

Delving deeper into the biology of the genes constituting the signature, two candidates—GALK1 and TFRC—stood out. These genes were not only highly expressed in bladder tumors but experimentally confirmed to have functional roles in promoting tumor cell proliferation and migration, critical aspects fueling cancer progression. The researchers used single-cell RNA sequencing to map these genes’ expression across various cell subtypes within the tumor niche, shedding light on the cellular ecosystems that drive metabolic reprogramming and immune evasion.

The study’s experimental arm validated these insights, demonstrating that knocking down GALK1 and TFRC in bladder cancer cell lines impaired cellular growth and motility, thereby underscoring their oncogenic potential. This multifaceted evidence converges to position the hypoxia-lactate metabolism axis as a pivotal determinant of tumor aggressiveness and a promising target for therapeutic intervention. Moreover, the integration of bioinformatics with bench-side experiments exemplifies the power of translational research in pushing the boundaries of cancer biology.

Importantly, this newly established signature transcends beyond mere prognostication: it offers a predictive lens into treatment responses. The data suggest that the metabolic state of a tumor, as reflected by hypoxia and lactate dynamics, might serve as a biomarker to predict responsiveness to both immunotherapy and chemotherapy. Such insights could revolutionize clinical decision-making, guiding oncologists toward more tailored and effective treatment regimens that consider patients’ unique tumor biology.

Another critical dimension illuminated by this research is the heterogeneity of bladder cancer at the molecular and microenvironmental levels. The identification of discrete subsets within bladder cancer, differentiated by their metabolic and immune landscapes, challenges the one-size-fits-all approach pervasive in clinical practice. Instead, it beckons a new era of precision oncology that integrates metabolic phenotyping with traditional pathological and molecular classifications.

Bioinformatics played a foundational role in this research, harnessing powerful computational techniques to integrate vast datasets—transcriptomics, single-cell analyses, clinical outcomes—into actionable insights. The use of random forests and Cox regression models provided statistical rigor, enabling the distillation of complex gene expression patterns into clinically relevant tools. Meanwhile, single-cell transcriptomic profiling offered unprecedented resolution, uncovering cellular players and pathways at a granular level.

The implications of this study extend beyond bladder cancer. It exemplifies the broader shift in oncology toward understanding the metabolic underpinnings of tumor biology and their interactions with the immune system. Such insights could stimulate analogous research in other malignancies where hypoxia and lactate metabolism play a central role, potentially unlocking novel prognostic markers and treatment targets across cancer types.

In sum, this pioneering study presents a multi-gene hypoxia and lactate metabolism-related signature that effectively stratifies bladder cancer patients by prognostic risk, immune contexture, and therapeutic sensitivity. It highlights GALK1 and TFRC as critical drivers of tumor aggressiveness, providing new avenues for targeted interventions. The confluence of bioinformatics analyses and experimental validation sets a new benchmark for cancer biomarker discovery and translational research.

With bladder cancer continuing to claim numerous lives annually, the development of reliable prognostic tools and tailored therapies stands as an urgent priority. This innovative prognostic signature offers a timely and impactful resource, capable of refining patient management and improving outcomes. As the field advances, integrating metabolic profiling into clinical workflows may become standard practice, ushering in more personalized and effective cancer care.

Looking ahead, further exploration of the interactions between hypoxia, lactate metabolism, and the immune microenvironment could reveal additional therapeutic vulnerabilities. Coupling this signature with emerging therapies targeting metabolic pathways could open up new frontiers in bladder cancer treatment. Ultimately, studies like these underscore the transformative potential of systems biology and precision oncology in combating cancer’s heterogeneity and complexity.

Subject of Research: Bladder cancer prognosis and molecular subtyping via hypoxia and lactate metabolism gene integration.

Article Title: Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.

Article References:
Zhao, Y., Li, P., Shen, Z. et al. Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence. BMC Cancer (2025). https://doi.org/10.1186/s12885-025-15010-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15010-1